Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Eli Lilly and Co. is looking to overturn a $20 million verdict finding it infringed a patent by selling its famous Cialis erectile dysfunction drug as a treatment for enlarged prostate ( Erfindergemeinschaft UroPep Gbr v. Eli Lilly and Co. , Fed. Cir., No. 15-cv-1202, notice of appeal filed, 9/25/17 ).In April, a jury awarded Erfindergemeinschaft UroPep Gbr $20 million in damages after finding Eli Lilly infringed UroPep’s U.S. Patent No. 8,791,124. UroPep asserted in a U.S. District Court for the Eastern District of Texas trial Eli Lilly infringed the patent by marketing and selling Cialis to treat benign prostatic hyperplasia (BPH), or enlarged prostate. The jury found Eli Lilly infringed the patent and the patent is valid.
The jury’s award compensated UroPep, a Hanover, Germany, company founded by research scientists at Hanover Medical School, for Cialis BPH sales up until the start of the trial. It also awarded UroPep a 5.68 percent royalty on Cialis BPH sales from then up until the patent expired in July.
With more than half of men over age 50 experiencing BPH, the market for treating the condition is lucrative. Cialis generated $2.5 billion in overall worldwide sales in 2016, according to its most recent annual report.
Eli Lilly sought to overturn the verdict or win a new trial, but the district court denied that request in a 79-page decision issued in August.
Eli Lilly now seeks relief in the U.S. Court of Appeals for the Federal Circuit. It submitted a notice of appeal Sept. 22, which was entered into the docket Sept. 25. A briefing schedule isn’t yet set.
Barnes & Thornburg LLP and Finnegan, Henderson, Farabow, Garrett & Dunner LLP represent Eli Lilly. Fish & Richardson PC; Bartlit Beck Herman Palenchar & Scott LLP; Gillam & Smith LLP represent UroPep.
To contact the reporter on this story: Greg Langlois in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)